Learn More
BACKGROUND We assessed the activity of gemcitabine (G) and cisplatin/gemcitabine (C/G) in patients with locally advanced (LA) or metastatic (M) (advanced) biliary cancers (ABC) for whom there is no standard chemotherapy. METHODS Patients, aged > or =18 years, with pathologically confirmed ABC, Karnofsky performance (KP) > or =60, and adequate(More)
Comparative genomic hybridization (CGH) was used to detect copy number changes of DNA sequences in the Ewing family of tumours (ET). We analysed 20 samples from 17 patients. Fifteen tumours (75%) showed copy number changes. Gains of DNA sequences were much more frequent than losses, the majority of the gains affecting whole chromosomes or whole chromosome(More)
BACKGROUND Effective systemic therapies for patients with advanced, progressive neuroendocrine tumours of the lung or gastrointestinal tract are scarce. We aimed to assess the efficacy and safety of everolimus compared with placebo in this patient population. METHODS In the randomised, double-blind, placebo-controlled, phase 3 RADIANT-4 trial, adult(More)
BACKGROUND Obtaining tissue for pancreatic carcinoma diagnosis and biomarker assessment to aid drug development is challenging. Circulating tumour cells (CTCs) may represent a potential biomarker to address these unmet needs. We compared prospectively the utility of two platforms for CTC enumeration and characterisation in pancreatic cancer patients in a(More)
BACKGROUND Cisplatin and gemcitabine is the standard first-line chemotherapy regimen for patients with advanced biliary tract cancer; expression of VEGF and its receptors is associated with adverse outcomes. We aimed to assess the effect of the addition of cediranib (an oral inhibitor of VEGF receptor 1, 2, and 3) to cisplatin and gemcitabine on(More)
In pre-clinical models the only two chemotherapy drugs which have been demonstrated to directly reduce the number of myeloid derived suppressor cells (MDSCs) are gemcitabine and 5-fluorouracil (5-FU). Here we analyse the dynamics of MDSCs, phenotyped as Lin-DR-CD11b+, in patients with advanced pancreatic cancer receiving the combination of gemcitabine and(More)
We reexamine the sensitivity of solar neutrino oscillations to noise in the solar interior using the best current estimates of neutrino properties. Our results show that the measurement of neutrino properties at KamLAND provides new information about fluctuations in the solar environment on scales to which standard helioseismic constraints are largely(More)
The feasibility of combining UFT plus leucovorin (LV) with alternating irinotecan and oxaliplatin was investigated in the first-line treatment of patients with advanced colorectal cancer. Twenty-five patients, median age 63 (range 24-79) years, World Health Organisation performance status 0-2 and median four marker lesions, received irinotecan 180 mg m(-2)(More)
On the 1st of April 1999, the National Institute of Clinical Excellence (NICE) was established to evaluate the clinical and cost effectiveness of various different medical technologies including pharmaceuticals. Initially, a technology is assessed, after which provisional and then final advisory documents (PAD and FAD) are produced prior to the publication(More)
BACKGROUND Accurate description of current practice within advanced colorectal cancer (CRC) specialties were needed to inform an economic evaluation of the UGT1A1 pharmacogenetic test for irinotecan in the United Kingdom. METHODS The study was based on a literature review and elicitation of expert opinion. The expert panel comprised 44 consultant(More)